Find disease awareness content and relevant supporting materials
NICE recommends use of Sarclisa plus pomalidomide and dexamethasone for multiple myeloma .- Sanofi
The UK's NICE has issued final guidance on the use of Sarclisa (isatuximab), from Sanofi, administered as an intravenous infusion, plus pomalidomide and dexamethasone, which is recommended for use within the Cancer Drugs Fund (CDF) as an option for treating relapsed and refractory multiple myeloma in adults.
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors).